vTv Therapeutics reports Q2 2026 results, reaffirms cadisegliatin trial timelines
The company said Phase 3 CATT1 enrollment should finish in the third quarter of 2026, with a related Phase 2a hybrid closed-loop study to begin before year end.
SEC filing